Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance

NCT07220694 | Recruiting

• 1 other identifier: SB20251021- A
• Study Type: interventional
• Target: 140
• Locations: 1 country
• Sites: 1

Brief Summary

This randomized, double-blind, placebo-controlled, 8-week clinical trial is designed to evaluate the effects of Sabroxy®, a standardized extract of Oroxylum indicum bark, on insulin resistance and cognitive function in adults with mild cognitive impairment and insulin resistance. A total of 120 participants (men and women, aged 40-80 years) who are non-smokers, with fasting glucose levels between 100-135 mg/dL, HOMA-IR value ≥ 2.0 to \< 4.0, and a Montreal Cognitive Assessment (MoCA) score below 26, will be enrolled. Eligible participants will be randomized (1:1) to receive either Sabroxy® (250 mg with 5 mg BioPerine®) or placebo, administered orally once daily for 8 weeks. The primary endpoint is the change in insulin resistance from baseline to Week 8, assessed using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR). The secondary endpoints include changes in: Cognitive performance, assessed using the Immediate Word Recall, Numeric Working Memory, Cognitive Failures Questionnaire (CFQ), and Montreal Cognitive Assessment (MoCA). Biomarkers of metabolic and neuronal function, including Brain-Derived Neurotrophic Factor (BDNF), high-sensitivity C-reactive protein (hs-CRP), fasting insulin, fasting glucose, and phosphorylated tau/amyloid beta (p-Tau/Aβ) ratio. Safety will be assessed through adverse event monitoring, vital signs, and routine clinical laboratory tests. The study will be conducted at a single site, San Francisco Research Institute (USA), in compliance with the Declaration of Helsinki, ICH-GCP guidelines, and 21 CFR Part 312 (where applicable). This study seeks to generate clinical evidence supporting the potential of Sabroxy® supplementation to improve glucose tolerance, reduce inflammation, and enhance cognitive function in individuals with early metabolic and neurocognitive dysfunctions.

Conditions

Insulin Resistance; Mild Cognitive Impairment; Cognitive Decline; Neurodegenerative Disorders

Keywords

BioPerine; Insulin Sensitivity; Cognitive Function; Memory Performance; Sabroxy

Outcome Measures

Primary Outcomes (1)

• Change in Insulin Resistance as Assessed by HOMA-IR

  Insulin resistance will be evaluated using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), calculated from fasting glucose and fasting insulin levels. The objective is to determine the mean change in HOMA-IR from baseline to Week 8 between the Sabroxy® and placebo groups.

  Prescreening -14 days and Week 8

Secondary Outcomes (10)

• Change in Cognitive Function Scores (Immediate Word Recall Test)

  Baseline- Day 1 and Week 8

• Change in Working Memory Performance (Numeric Working Memory Test)

  Baseline- Day 1 and Week 8

• Change in Self-Perceived Cognitive Failures (Cognitive Failures Questionnaire-CFQ)

  Baseline- Day 1 and Week 8

• Change in Montreal Cognitive Assessment (MoCA) Total Score

  Prescreening -14 days and Week 8

• Change in Serum Brain-Derived Neurotrophic Factor (BDNF)

  Prescreening -14 days and Week 8

Study Arms (2)

Dietary Supplement (Sabroxy®)

ACTIVE COMPARATOR

Subjects are to take two capsules with water in the am.

Dietary Supplement: Sabroxy®

Placebo (Inactive capsule)

PLACEBO COMPARATOR

Subjects are to take two capsules with water in the am.

Other: Placebo

Interventions

Sabroxy® DIETARY_SUPPLEMENT

Sabroxy® is a standardized extract of Oroxylum indicum bark formulated with BioPerine® (black pepper extract) to enhance bioavailability. Each capsule contains 250 mg of Sabroxy® and 5 mg of BioPerine®, administered once daily after breakfast with water for 8 weeks. Sabroxy® is standardized for bioactive flavonoids such as oroxylin A, baicalein, and chrysin, which are known for their antioxidant, neuroprotective, and anti-inflammatory properties. The product will be supplied by Sabinsa Corporation (East Windsor, NJ, USA) under Good Manufacturing Practice (GMP) conditions and will be packaged in identical capsules to maintain blinding. The intervention aims to evaluate the effects of Sabroxy® on insulin resistance, inflammation, and cognitive performance in adults with mild cognitive impairment and insulin resistance.

Also known as: Oroxylum indicum bark extract, Sabroxy® 250 mg + BioPerine® 5 mg

Dietary Supplement (Sabroxy®)

Placebo OTHER

The placebo consists of identical capsules containing inert excipients (microcrystalline cellulose and magnesium stearate) with no active botanical ingredients. The capsules are identical in appearance, weight, color, and packaging to the Sabroxy® capsules to maintain blinding. Participants assigned to the placebo group will receive one capsule orally once daily after breakfast with water for 8 weeks. The placebo will be manufactured and supplied under Good Manufacturing Practice (GMP) conditions by Sabinsa Corporation (East Windsor, NJ, USA). This control group will enable comparison of Sabroxy®'s efficacy and safety against a non-active formulation to validate clinical outcomes.

Also known as: Matching Placebo Capsule

Placebo (Inactive capsule)

Eligibility Criteria

• Age: 40 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Female or male, adults grouped by age as follows 2 groups of 70 patients each (35 active and 35 placebo )
• GROUP 1 = aged 40 - 60, and
• GROUP 2 = aged 61 - 80
• In good general health
• Screening HOMA-IR value ≥ 2.0 to \< 4.0
• Screening fasting glucose 100 to 135 mg/dL
• Screening MoCA less than 26

You may not qualify if:

• Having been diagnosed with known allergies to any ingredients in the study product.
• Relevant history or presence of any medical disorder potentially interfering with this study (e.g., malabsorption, chronic gastrointestinal diseases, severe depression, cardiovascular disease occurrence within the last 3 months, etc.),
• Regular intake of medications or supplements known to affect glucose tolerance
• Breastfeeding, pregnant, or planning to become pregnant during the study, according to the subject's self-report.
• Having a pregnant partner or a partner who is planning to become pregnant during the study period or is unwilling or unable to use an acceptable method of contraception.
• Having a history of skin cancer within the past 5 years.
• Having a history of immunosuppression/immune deficiency disorders (including HIV infection, it has been AIDS, multiple sclerosis, Crohn's disease, rheumatoid arthritis), organ transplant (heart, kidney, etc.), or currently using oral or systemic immunosuppressive medications and biologics (e.g., azathioprine, belimumab, Cimzia®, Cosentyx®, cyclophosphamide, cyclosporine, Enbrel®, Humira®, Imuran®, Kineret®, mycophenolate mofetil, methotrexate, Orencia®, prednisone, Remicade®, Rituxan®, Siliq™, Simponi®, Stelara®, Taltz®) and/or undergoing radiation or chemotherapy as determined by study documentation.
• Currently using or having regularly used corticosteroids (systemic or topical, not nasal or ocular) within the past 4 weeks (including but not limited to betamethasone, clobetasol, desoximetasone, diflorasone, fluocinonide, halcinonide, and halobetasol).
• Having a disease such as asthma, diabetes, epilepsy, hypertension, hyperthyroidism, or hypothyroidism that is not controlled by diet or medication. Individuals having multiple health conditions may be excluded from participation even if the conditions are controlled by diet, medication, etc.
• Having started a long-term medication within the last 2 months.
• Having planned surgeries or invasive medical procedures during the study. Non-invasive medical procedures or surgeries will be reviewed for their impact on the study outcome and acceptability by the Investigator or designee.
• Currently participating in any other clinical trial at SFRI or another research facility or doctor's office.
• Having participated in any other clinical trial that evaluates or applies interventions to the same body system, organ, or condition being studied in this trial within 12 weeks prior to the screening visit at SFRI or another research facility or doctor's office.
• Note - Medications for treatment of chronic diseases that do not affect the metabolism of the study product will be permitted and will be judged individually regarding interference with the study by an investigator.

Sponsors & Collaborators

• SF Research Institute, Inc.: lead
• Sabinsa Corporation: collaborator

Study Sites (1)

San Francisco Research Institute

San Francisco, California, 94132, United States

RECRUITING

MeSH Terms

Conditions

Insulin Resistance; Cognitive Dysfunction; Neurodegenerative Diseases

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Cognition Disorders; Neurocognitive Disorders; Mental Disorders; Nervous System Diseases

Central Study Contacts

Dr. John Ademola

CONTACT

415-845-4638; jademola@sfinstitute.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2025
• First Posted: October 24, 2025
• Study Start: January 29, 2026
• Primary Completion: March 28, 2026
• Study Completion: April 29, 2026
• Last Updated: January 28, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)